Dow Drug Patent Portfolio
Dow owns 2 orange book drugs protected by 4 US patents Given below is the list of Dow's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10653656 | Topical pharmaceutical compositions for treating skin conditions | 22 Aug, 2038 | Active |
| US11324710 | Topical pharmaceutical compositions for treating skin conditions | 22 Aug, 2038 | Active |
| US6517847 | Topical gel delivery system | 03 Aug, 2020 | Expired |
| US5670547 | Moisturizing vehicle for topical application of vitamin A acid | 23 Sep, 2014 | Expired |
Latest Legal Activities on Dow's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Dow.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Oct, 2025 | US11324710 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2023 | US10653656 |
|
Recordation of Patent Grant Mailed
Critical
| 10 May, 2022 | US11324710 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 May, 2022 | US11324710 |
|
Email Notification
Critical
| 21 Apr, 2022 | US11324710 |
|
Issue Notification Mailed
Critical
| 20 Apr, 2022 | US11324710 |
| Dispatch to FDC | 06 Apr, 2022 | US11324710 |
|
Application Is Considered Ready for Issue
Critical
| 06 Apr, 2022 | US11324710 |
|
Issue Fee Payment Verified
Critical
| 05 Apr, 2022 | US11324710 |
|
Issue Fee Payment Received
Critical
| 05 Apr, 2022 | US11324710 |
| Mailing Corrected Notice of Allowability | 22 Mar, 2022 | US11324710 |
|
Email Notification
Critical
| 22 Mar, 2022 | US11324710 |
|
Information Disclosure Statement considered
Critical
| 15 Mar, 2022 | US11324710 |
| Corrected Notice of Allowability | 15 Mar, 2022 | US11324710 |
|
Pubs Case Remand to TC
Critical
| 14 Mar, 2022 | US11324710 |
Dow's Family Patents
Clinical Trials
Recent Clinical Trials by Dow:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer | State University of New York - Downstate Medical Center | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines | Maria Sklodowska-Curie National Research Institute of Oncology | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Effect of Preoperative Tramadol and Naproxen Sodium on Post Operative Pain | Dow University of Health Sciences | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Triple Antibiotic Paste vs Simvastatin for Lesion Sterilization and Tissue Repair in Primary Molars. | Dow University of Health Sciences | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |
Dow Drug List
Given below is the complete list of Dow's drugs and the patents protecting them.
1. Altreno
Altreno is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10653656 | Topical pharmaceutical compositions for treating skin conditions |
22 Aug, 2038
(11 years from now)
| Active |
| US11324710 | Topical pharmaceutical compositions for treating skin conditions |
22 Aug, 2038
(11 years from now)
| Active |
| US6517847 | Topical gel delivery system |
03 Aug, 2020
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Altreno's drug page
2. Atralin
Atralin is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5670547 | Moisturizing vehicle for topical application of vitamin A acid |
23 Sep, 2014
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atralin's drug page